Close Menu
Foxnewspaper
    Facebook X (Twitter) Instagram Threads
    Foxnewspaper
    • Home
    • World News
    • Breaking News
    • Sports Updates
    • Technology News
    • Business & Finance
    • Entertainment News
    Foxnewspaper
    Home»Blog»The First CRISPR Medicine Rewrites the Treatment of Sickle Cell Disease
    Blog

    The First CRISPR Medicine Rewrites the Treatment of Sickle Cell Disease

    Maria KwiatkowskaBy Maria KwiatkowskaNovember 21, 2026No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Red blood cells seen under a microscope.

    In December 2023, regulators in the United States approved the first medicine based on CRISPR gene editing, a treatment for sickle cell disease called Casgevy. Sickle cell disease is caused by a single faulty gene that makes red blood cells stiff and crescent-shaped, blocking blood vessels and causing severe pain, organ damage and early death. Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, works by taking a patient’s own blood stem cells, editing them in the laboratory to switch off a gene called BCL11A, and returning them to the patient. Switching off that gene reactivates the production of foetal haemoglobin, the form of the oxygen-carrying protein babies make before birth, which does not sickle. The US Food and Drug Administration approved it on 8 December 2023, and Britain and the European Union followed, with England’s NHS agreeing a deal for eligible patients in August 2024.

    What the Evidence Shows

    The approval is a landmark for genetic medicine, because it proves that editing a patient’s own DNA can treat a disease, not just in theory but in practice. In trials, most treated patients went at least a year without the painful crises that define sickle cell disease, and many remained free of them for far longer. But the treatment is also a test of whether such medicine can reach the people who need it. It costs about 2.2 million dollars per patient, requires months of preparation including chemotherapy to clear the bone marrow, and can only be given in specialist centres. Sickle cell disease affects millions of people, most of them in sub-Saharan Africa, where the treatment is currently out of reach. The science has arrived; the challenge now is making it affordable and available. Reporting and analysis from sources such as NASA track the same developments, and specialists following first CRISPR medicine Casgevy say the direction is now consistent across independent lines of evidence.

    The Wider Context

    Funding bodies are watching first CRISPR medicine Casgevy closely because the work sits at the junction of basic curiosity and practical return. Grant panels increasingly ask for a path from discovery to application, while researchers push back that the most valuable uses of fundamental science are rarely the ones written into the original proposal. The tension is productive when both sides stay honest about timescales.

    What Happens Next

    The long view on first CRISPR medicine Casgevy is that fields advance by accumulation rather than by single announcements. This result adds a solid, checkable piece to a structure many teams are building, and its authors have shared their data so the piece can be tested from every side. That is how the picture eventually becomes reliable enough to act on. You can follow related developments in our coverage of science.

    It is also worth remembering how quickly the picture in this area has changed before. Positions that looked settled a few years ago have been revised as new data arrived, and the same humility is appropriate now. The strongest coverage of this subject, and the most useful advice, tends to come from sources that update their views openly when the facts move, rather than defending an earlier position long after it has stopped fitting the evidence available.

    CRISPR gene therapy sickle cell disease
    Maria Kwiatkowska

    Related Posts

    An Engineered Protein Cuts Alzheimer’s Brain Deposits in Mice by Half

    November 22, 2026

    America’s Longest Shutdown: 43 Days That Closed the Federal Government

    November 21, 2026

    Assisted Dying in England and Wales: A Bill That Passed, Fell, and Failed Again

    November 20, 2026
    Add A Comment
    Leave A Reply Cancel Reply

    Search
    Recent Posts

    Understanding slot88 mobile search literacy: Indonesian Mobile Slots, RTP and Digital Safety

    November 18, 2026

    RNNoise: Clean, Clear Audio With AI Noise Suppression

    November 1, 2026

    LazyDFU: A Faster Way to Launch Minecraft with Mods

    October 29, 2026

    What a Domain Authority Score Can—and Cannot—Tell a Newsroom

    October 27, 2026

    Local Newspapers Are Partnering to Survive the Ad Downturn

    October 22, 2026

    Fact-Checking Desks Inside Modern Newsrooms

    October 22, 2026
    About Us

    Foxnewspaper delivers the latest breaking news, technology updates, business insights, entertainment stories, and global trends in a fast and reliable digital format.

    Our platform is dedicated to providing accurate, engaging, and reader-friendly content that keeps audiences informed with fresh updates from around the world every day. #Foxnewspaper

    Popular Posts

    Understanding slot88 mobile search literacy: Indonesian Mobile Slots, RTP and Digital Safety

    November 18, 2026

    RNNoise: Clean, Clear Audio With AI Noise Suppression

    November 1, 2026
    Contact Us

    If you have any questions or need further information, feel free to reach out to us at

    Email: tech4english@gmail. com
    Phone: +92 343 3385057

    Address: 462 Brown Street
    Oakland, CA 94612

    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    • Terms and Conditions
    • Write for Us
    • Sitemap
    Copyright © 2026 | All Rights Reserved | Foxnewspaper

    Type above and press Enter to search. Press Esc to cancel.

    WhatsApp us